Kura Oncology, Inc.
12730 High Bluff Drive
Suite 400
San Diego, CA 92130
(858) 500-8800
August 14, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Jeffrey Gabor |
| Re: | Kura Oncology, Inc. |
Registration Statement on Form S-3
File No. 333-241663
Ladies and Gentlemen:
Kura Oncology, Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:00 p.m. Eastern Time on Tuesday, August 18, 2020, or as soon thereafter as is practicable. The Registrant also hereby requests a copy of the written order verifying the effective date.
If you have any questions regarding this request, please contact Charles J. Bair of Cooley LLP at (858) 550-6142.
Sincerely,
KURA ONCOLOGY, INC.
| By: | /s/ Marc Grasso | |
| Marc Grasso, M.D. | ||
| Chief Financial Officer and Chief Business Officer |
| cc: | Charles J. Bair, Cooley LLP |